LATEST NEWS

Vaccine Could Prevent About 92% of HPV Cancers
CDC Reports Good News, Bad News
Off-Label Medication Use Rising Among Children
One in Five Kids’ Office Visits Results in an Off-Label Rx
Opioid Maker Purdue Files for Bankruptcy
Related Settlement Would End Many but Not All Lawsuits
Ibsrela Wins FDA Approval for IBS-C
Chronic Kidney Patients With Hyperphosphatemia May Be Another Market for the Drug
Some Zantac Tainted With Low Levels of Carcinogen
Nitrosamine Impurity Also Affects Other Ranitidine Drugs
Fixing Vaginal Prolapse: Two Methods, Similar Results
Mesh Implants, Now Banned by FDA, Work as Well as Hysterectomy
Antibiotics May Affect Some Immune Responses to Flu Vaccine
Disrupting Gut Microbiome Could Be Key
‘Fear-Reducing’ Medication Holds Promise for PTSD
Drug Boosts Levels of Natural Endocannabinoids
'Persister' Bacteria May Pass Along Resistance Genes
Judicious Use of Antibiotics May Not Be Enough To Defeat Bacteria That Carry On By Going Into a Dormant State
Taking an Indirect Route to Stopping Pancreatic Cancer
KRAS Oncogene Is a Problematic Target So Researchers Are Trying Workdarounds
Research Explores How Brain Suppresses Drug Cravings
Understanding Neural Ensembles in Infralimbic Cortex May Lead To Improved Addiction Treatment

P&T September 2019
Table of Contents

Features

Antibiotic Breakpoints: How Redefining Susceptibility Preserves Efficacy and Improves Patient Care
Carbapenems are a primary treatment for infections from multidrug-resistant bacterial pathogens. To maintain their efficacy and control the emergence of further resistance, breakpoints that correspond to recommended doses with appropriate PK/PD target attainment are paramount.

Industry announcements

More industry announcements